MLH1

Across TCGA pan-cancer cohorts, MLH1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MLH1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MLH1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MLH1 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where MLH1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MLH1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.373	<.001	9	view →
LSCC	Male	II,III,IV	+0.467	<.001	8	view →
HNSC	Male	IV	+0.241	<.001	8	view →
CCRCC	Male	IV	−0.220	.006	6	view →
COAD	All	All	+0.334	.010	5	view →
PDAC	Female	All	−0.166	.024	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MLH1–LUAD

Open the LUAD breakdown →